R3 Vascular Inc.
PrivateLast Round
Series B
May 9, 2024
Est. Valuation
$145M
Total Funding Raised
$104.8M
Company Overview
R3 Vascular Inc. operates in Healthcare & Life Sciences and is based in Mountain View, California. Its latest recorded funding round was a Series B round in May 2024.
R3 Vascular Inc. is a medical device company that develops bioresorbable, sirolimus-coated vascular scaffolds for the treatment of peripheral arterial disease.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
R3 Vascular Inc. Comparables
Compare R3 Vascular Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| REVA Medical | 89% | |
| Micro Medical Solutions | 85% | |
| STENTiT | 85% |
For institutional investors. Book with your work email.
R3 Vascular Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 9, 2024 | ||||
| Series A | Oct 8, 2020 |
For institutional investors. Book with your work email.
R3 Vascular Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | Series B |
| 415 | Series A, Series B |
| 415 Capital | Series B, Series A |
| Wexford Capital | Series A |
| HBM Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 24, 2026
Grew 18% QoQ, from 28 to 33 employees.
- Oct 8, 2020
$18M round led by 415 Capital
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresSep 21, 2026
R3 Vascular Inc. appoints Lisa Wipperman Heine to its Board of Directors in California on Sept. 21st '26, adding her more than three decades of medical technology innovation experience.
- hiresSep 21, 2026
R3 Vascular Inc. appoints Lisa Wipperman Heine to its Board of Directors in California on Sep 21st '26, bringing more than three decades of medical technology innovation, clinical strategy, reimbursement and commercialization experience.
- hiresAug 24, 2026
R3 Vascular Inc. appoints Robert Spanos as Vice President, Global Market Development in California on Aug 24th '26, as it accelerates clinical trial enrollment, market development, scalability, and future commercialization.
- hiresAug 24, 2026
R3 Vascular Inc. hires Katie, who brings finance leadership experience from Kronos Bio.
- hiresAug 24, 2026
R3 Vascular Inc. appoints Robert Spanos as Vice President, Global Market Development in California on Aug 24th '26, as the company accelerates clinical trial enrollment, market development, scalability, and future commercialization.
For institutional investors. Book with your work email.
R3 Vascular Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about R3 Vascular Inc.'s valuation, stock price, and market status.
Is R3 Vascular Inc. a public or private company?
R3 Vascular Inc. is a private company.
What is the current stock price of R3 Vascular Inc.?
R3 Vascular Inc. is a private company, so its shares have no public market price. Caplight tracks R3 Vascular Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is R3 Vascular Inc. worth (valuation)?
R3 Vascular Inc.'s valuation is estimated at $145.0M based on funding round data.
Can I buy R3 Vascular Inc. stock?
R3 Vascular Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was R3 Vascular Inc.'s last funding round?
R3 Vascular Inc.'s most recent funding round was Series B on May 9, 2024.
Who are the main investors in R3 Vascular Inc.?
Key investors in R3 Vascular Inc. include Deerfield Management, 415, 415 Capital.
Will R3 Vascular Inc. IPO soon?
No public IPO plans have been announced for R3 Vascular Inc..
How can I track R3 Vascular Inc. secondary market activity?
Caplight tracks bids, offers, and trades in R3 Vascular Inc.'s shares on secondary markets.